AVANOS MEDICAL INC
AVNSNYSETrading Snapshot
- Day Range
- $24.98 β $25.00
- 52-Week Range
- $10.64 β $25.49
- Volume (shares)
- 23,068
- Avg Volume (shares)
- β
- Shares Outstanding
- 46.9M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $701M
- Last Q Revenue
- $182M
- P/E Ratio
- β
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-1.61
- Dividend Yield
- β
- Dilution (1yr)
- +0.9%
AVANOS MEDICAL INC
AVNSAbout AVANOS MEDICAL INC
Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates
News unavailable.